Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Public ClinicalTrials.gov record NCT07626411. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-EVEREST)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Study identification
- NCT ID
- NCT07626411
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 15,364 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 9, 2026
- Primary completion
- Sep 10, 2029
- Completion
- Dec 9, 2029
- Last update posted
- Aug 24, 2026
2026 – 2029
United States locations
- U.S. sites
- 8
- U.S. states
- 5
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| SEC Clinical Research | Dothan | Alabama | 36305 | Recruiting |
| Radin Cardiovascular Medical Group | Newport Beach | California | 92663 | Recruiting |
| Southern California Heart Specialists | Pasadena | California | 91105 | Recruiting |
| Sec Clinical Research | Pensacola | Florida | 32503 | Recruiting |
| Monroe Research, LLC | West Monroe | Louisiana | 71291 | Recruiting |
| PharmaTex Research | Amarillo | Texas | 79106 | Recruiting |
| West Houston Area Clinical Trial Consultants, LLC | Houston | Texas | 77094 | Recruiting |
| Permian Research Foundation | Odessa | Texas | 79761 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Atrial Fibrillation (AF) trials
Other public records listing Atrial Fibrillation (AF). Sorted by last update posted; newest first. Not a recommendation.
- NCT07779213: Detection of Atrial Fibrillation Using PPG From Smartphone Cameras Recruiting
- NCT06707688: Abbott Medical - VERITAS Study Active, not recruiting
- NCT07711327: Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy Not yet recruiting
- NCT07620262: Prospective Remapping With Concomitant Left Atrial Appendage Occlusion to Ensure Durable Electroporation Study Recruiting
- NCT07705425: EPX-HTG for Structural Heart Procedures Not yet recruiting
- NCT05712200: Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07626411, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 24, 2026 · Synced Aug 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07626411 live on ClinicalTrials.gov.